<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04433169</url>
  </required_header>
  <id_info>
    <org_study_id>2020HNRT02</org_study_id>
    <nct_id>NCT04433169</nct_id>
  </id_info>
  <brief_title>All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck</brief_title>
  <acronym>Aplus</acronym>
  <official_title>A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, randomized controlled clinical intervention study to
      evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with
      recurrent metastatic adenoid cystic carcinoma of the head and neck.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (CR+PR)</measure>
    <time_frame>6 months</time_frame>
    <description>Objective Response Rate as defined by RECIST 1.1 after induction therapy followed by definitive chemoradiation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Grade 3-4 Toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Time to death or progression defined by imaging of target lesions via CT or MRI scan every 3 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adenoid Cystic Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATRA 20 mg, three times a day (tid), for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles; combined with the treatment regimen chosen by the investigator since Day 6 of cycle 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigator chooses the treatment regimen based on the following regimens (including but not limited to: 1. VEGFR inhibitor; 2. chemotherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans Retinoic Acid</intervention_name>
    <description>ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Ailike</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGFR inhibitor</intervention_name>
    <description>VEGFR inhibitor</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age ≥ 18 years, male or female; 2. ECOG PS (performance status) score: 0-1; 3.
        Pathologically or histologically confirmed advanced, recurrent/metastatic ACC, with
        measurable disease (≥10 mm by spiral CT scan, meeting RECIST 1.1 criteria); 4. Patients
        with therapeutic indications; 5. Main organ functions normal, i.e., meeting the criteria
        below:

          1. Criteria for routine blood test: (no blood transfusion within 14 days)

               1. HB ≥ 90 g/L;

               2. WBC ≥ 3.5 × 109/L and &lt; 10 × 109/L;

               3. ANC ≥ 1.5 × 109/L;

               4. PLT ≥ 80 × 109/L

          2. Criteria for biochemical tests:

               1. BIL &lt; 1.25 × upper limit of normal (ULN)

               2. ALT and AST &lt; 2.5 × ULN; in the presence of metastases to liver, ALT and AST &lt; 5
                  × ULN;

               3. Serum Cr ≤ 1 × ULN, endogenous creatinine clearance &gt; 50 mL/min (Cockcroft-Gault
                  equation); 5. Subjects who volunteer to participate in this study, sign the
                  informed consent, have good compliance and cooperate in follow-up; 6. Patients
                  who, in the doctor's opinion, can benefit from the treatment.

        Exclusion Criteria:

          1. Previous or existing concomitant malignancies except cured skin basal cell carcinoma
             or cervical carcinoma in situ;

          2. Coagulation abnormal (INR&gt;1.5, APTT&gt;1.5×ULN), history of gastrointestinal hemorrhage
             in the past 6 months or bleeding tendency [e.g., presence of active ulcer focus in the
             stomach, stool occult blood (++), melena and/or hematemesis, hemoptysis in the past 3
             months];

          3. Confirmed hypersensitivity to ATRA;

          4. Grade I and above coronary artery diseases, arrhythmias [including QTc prolongation
             (males: &gt; 450 ms, females: &gt; 470 ms)] and cardiac dysfunction;

          5. Presence of multiple factors affecting oral administration (e.g. dysphagia, nausea,
             vomiting, chronic diarrhea and intestinal obstruction, etc.);

          6. Pregnant or lactating women;

          7. History of psychotropic abuse with abstinence failure, or existing mental disorder;

          8. Participation in other drug clinical trials within 4 weeks;

          9. Other concomitant diseases which seriously jeopardize the patient's safety or prevent
             the patient from completing the study, as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guopei Zhu, M.D</last_name>
    <phone>021-23271699</phone>
    <phone_ext>5665</phone_ext>
    <email>antica@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lulu Ye, Master</last_name>
      <phone>021-23271699</phone>
      <phone_ext>5665</phone_ext>
      <email>yee166@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

